右美托咪定降低脓毒性休克患者死亡率:一项随机对照试验(DecatSepsis)
本研究为开放标签随机对照试验,纳入90例脓毒性休克且心率>90次/分的患者,无论是否接受机械通气。右美托咪定组以心率60-90次/分为目标输注48小时,机械通气患者两组均接受常规镇静。主要结果为院内死亡率,右美托咪定组风险比(RR)为0.68(95%CI 0.43-1.07,P=0.091),未达统计学显著。右美托咪定可能减少肾上腺素补救、持续性房颤、APACHE II评分和CRP,但研究把握度不足以检测死亡率和去甲肾上腺素等效剂量的降低。
要点
- 在脓毒性休克且心率>90次/分的患者中,右美托咪定组院内死亡风险RR为0.68(95%CI 0.43-1.07,P=0.091),未达统计学显著。
- 右美托咪定组去甲肾上腺素等效剂量为0.55 μm/kg/min(IQR 0.37-0.82)vs 对照组0.61 μm/kg/min(IQR 0.47-0.89),P=0.121。
- 右美托咪定减少肾上腺素补救输注,相对风险降低0.6(95%CI 0.06-0.93,P=0.025)。
- 右美托咪定组持续性房颤的RR为0.47(95%CI 0.21-0.99,P=0.05)。
- 右美托咪定降低第3天APACHE II评分(差值-6,95%CI -10至-2,P=0.003)和平均CRP浓度(差值-40 mg/dL,95%CI -78至-3.4 mg/dL,P=0.033)。
适用人群与场景
- 脓毒性休克且心率>90次/分的成人患者,无论是否接受机械通气。
诊断标准与关键阈值
- 心率>90次/分作为纳入标准;右美托咪定输注目标为维持心率60-90次/分。
处置流程与药物剂量
- 右美托咪定以心率校准输注48小时,目标心率60-90次/分;机械通气患者两组均接受常规镇静。
研究设计与关键结果
- 研究类型:开放标签随机对照试验;样本量90例;人群:脓毒性休克且心率>90次/分的成人患者;干预:右美托咪定心率校准输注48小时(目标心率60-90次/分)vs 对照;主要终点:院内死亡率RR 0.68(95%CI 0.43-1.07,P=0.091)。
- 右美托咪定组前3天ICU平均心率降低11.2次/分(95%CI -17至-5次/分,P<0.001)。
- 去甲肾上腺素等效剂量:右美托咪定组0.55 μm/kg/min(IQR 0.37-0.82)vs 对照组0.61 μm/kg/min(IQR 0.47-0.89),P=0.121。
- 肾上腺素补救输注:右美托咪定组相对风险降低0.6(95%CI 0.06-0.93,P=0.025)。
- 持续性房颤:RR 0.47(95%CI 0.21-0.99,P=0.05)。
- 第3天APACHE II评分:右美托咪定组降低6分(95%CI -10至-2,P=0.003)。
- 平均CRP浓度:右美托咪定组降低40 mg/dL(95%CI -78至-3.4 mg/dL,P=0.033)。
证据类型、等级与局限
- 证据类型:开放标签随机对照试验;研究把握度不足以检测院内死亡率或去甲肾上腺素等效剂量的降低。
对床旁实践的改变
- 作者认为,右美托咪定可能减少脓毒性休克患者(心率>90次/分)的肾上腺素补救输注、持续性房颤、APACHE II评分和CRP。
- 研究把握度不足,未能证实右美托咪定降低院内死亡率或去甲肾上腺素等效剂量。
指南或共识出处
- 临床试验注册:ClinicalTrials.gov;注册号:NCT05283083。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis, especially septic shock, and its complications have been linked to the hyperadrenergic stress response.
RESEARCH QUESTION: Does decatecholaminization with dexmedetomidine lower the in-hospital mortality in patients with septic shock?
STUDY DESIGN AND METHODS: This open-label randomized controlled trial assessed the effects of a heart rate (HR)-calibrated dexmedetomidine infusion on in-hospital mortality in patients with septic shock and HR of > 90 beats/min, regardless of whether they are receiving mechanical ventilation. Dexmedetomidine was infused for 48 h to maintain the HR at 60 to 90 beats/min. Mechanically ventilated patients received conventional sedation in both groups. Other outcomes were the norepinephrine equivalent dose, the need for additional vasopressor, Acute Physiology and Chronic Health Evaluation (APACHE) II score, persistent atrial fibrillation (AF), and C-reactive protein (CRP) level.
RESULTS: In 90 patients of either sex, dexmedetomidine reduced the mean HR over the first 3 days in the ICU by 11.2 beats/min (95% CI, -17 to -5 beats/min; P < .001). The in-hospital mortality risk ratio (RR) was 0.68 (95% CI, 0.43-1.07; P = .091). The dexmedetomidine group received a norepinephrine equivalent dose of 0.55 μm/kg/min (interquartile range [IQR], 0.37-0.82 μm/kg/min) vs 0.61 μm/kg/min (IQR, 0.47-0.89 μm/kg/min; P = .121). Dexmedetomidine reduced the epinephrine infusion rescue (relative risk reduction, 0.6; 95% CI, 0.06-0.93; P = .025). The RR of persistent AF was 0.47 (95% CI, 0.21-0.99; P = .05). Dexmedetomidine reduced the median APACHE II score on the third day by -6 (95% CI, -10 to -2; P = .003) and the mean CRP concentration by -40 mg/dL (95% CI, -78 to -3.4 mg/dL; P = .033).
INTERPRETATION: The study was underpowered to detect a reduction in in-hospital mortality or norepinephrine equivalent dose in patients with septic shock with dexmedetomidine. However, dexmedetomidine may reduce epinephrine infusion rescue, persistent AF, APACHE II score, and CRP.
CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT05283083; URL: www.
CLINICALTRIALS: gov.
参考来源
- Ezz Al-Regal AR, Ramzy EA, Atia AAA, et al. Dexmedetomidine for Reducing Mortality in Patients With Septic Shock: A Randomized Controlled Trial (DecatSepsis). Chest. 2024. PMID: 39004217. doi:10.1016/j.chest.2024.06.3794
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。